Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Immatics N.V.

Report initial Phase 1a dose escalation data for IMA201, IMA202, and IMA203

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
6 Jan 2021
Due
30 Jun 2021
Checked
24 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“ACTengine® IMA201, 202, 203: Initial Ph1a dose escalation read-out”

What we found

Evidence strength A What the grades mean

The company did not report initial Phase 1a dose escalation data for IMA201, IMA202, and IMA203 by the 1H 2021 deadline, instead reporting data for IMA203 in November 2021 and IMA201/202 in November 2021.

  • A
    Immatics N.V. 6-K filed 2021-07-15 Regulatory filing · published 15 Jul 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 7663a05af0b2
    “Upcoming R&D Milestones in 2021 35 1H 2021 2H 2021 ACTengine ® IMA201, 202, 203: Initial dose escalation read - out” ✓ confirmed on the page
  • A
    Immatics N.V. 6-K filed 2021-11-09 Regulatory filing · published 9 Nov 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint b963bb32acb4
    “ACTengine® IMA203 PRAME – Phase 1a Dose Escalation Interim Update” ✓ confirmed on the page
  • A
    Immatics N.V. 20-F filed 2022-03-23 Regulatory filing · published 23 Mar 2022 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 5badada0f76f
    “In November 2021, we reported interim data from the Phase 1 dose-escalation stage of our IMA201 and IMA202 clinical trials.” ✓ confirmed on the page

Market reaction: the shares moved -7.1% against the S&P 500 over the three sessions around the disclosure (8 Nov 2021 to 11 Nov 2021). What this measures

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Report
Deliverable
Phase 1a dose escalation data
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
  4. Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Immatics N.V.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-IMTX-021121 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.